What is the current bupropion market size?

The bupropion market size was valued at approximately USD 1.2 billion in 2023, driven by rising demand for smoking cessation and depression treatments.

What is the expected growth rate of the bupropion market?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, supported by increasing mental health awareness and obesity management trends.

What are the key drivers for the bupropion market?

Key drivers include rising prevalence of mental health disorders, growing obesity treatment adoption, and expanding off-label use in chronic pain management.

What challenges does the bupropion market face?

Challenges include adverse effects like seizures, regulatory scrutiny over misuse, and competition from newer antidepressants such as SSRIs and SNRIs.

Which regions lead the bupropion market?

North America dominates due to high healthcare spending, followed by Europe, while Asia-Pacific is emerging rapidly due to expanding healthcare infrastructure.

Who are the top companies in the bupropion market?

Leading players include Otsuka Pharmaceutical, Takeda, Supernus Pharmaceuticals, and Teva Pharmaceuticals, commanding significant market shares.

What future opportunities exist in the bupropion market?

Future opportunities lie in developing extended-release formulations, expanding into underserved regions, and exploring use in combination therapies for metabolic disorders.

How does technology impact the bupropion market?

Advancements in drug delivery systems, AI-driven patient monitoring, and digital therapeutics are enhancing bupropion's efficacy and market adoption potential.

What is the regulatory landscape for bupropion?

Regulatory agencies like FDA and EMA enforce strict approvals, monitor safety profiles, and require post-marketing studies to ensure bupropion's long-term safety and efficacy.

bupropion Growth Drivers & Forecast Analysis 2033

bupropion by Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Types (Immediate Release (IR), Sustained Release (SR), Extended Release (XR)), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

bupropion Market Size | CAGR 7.2 Forecast 2033

bupropion Growth Drivers & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

bupropion Market Overview

Bupropion Market Definition: Bupropion, a norepinephrine-dopamine reuptake inhibitor, is a cornerstone in treating depression and aiding smoking cessation. Its relevance stems from rising mental health awareness and growing demand for non-nicotine cessation therapies. The bupropion market size is projected to exceed USD 3.3 billion by 2033, reflecting a growth outlook of 5.8% CAGR during 2026–2033. This market forecast underscores its pivotal role in expanding industry expansion across psychiatric and nicotine replacement sectors.

Macroeconomic drivers include surging antidepressant prescriptions (projected at 12% global increase by 2030) and regulatory tailwinds for generic bupropion variants, which account for 40% of current prescriptions. Key forces shaping the industry are: 1) Technological shifts toward extended-release formulations (e.g., Wellbutrin XL) enhancing patient compliance, and 2) Supply-chain dynamics favoring Asia-Pacific, now the fastest-growing region due to cost-competitive manufacturing. North America remains the largest market, driven by high smoking cessation rates and robust R&D pipelines. Strategic partnerships among key players, such as Orexo’s collaborations for bupropion SR, further intensify competitive intensity.

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	4.01 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GSK; Actavis Laboratories; Anchen Pharmaceuticals; Epic Pharma; Impax Laboratories; InvaGen (a Cipla subsidiary); Prinston Pharmaceutical; ScieGen Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of depression and smoking cessation demand is fueling the bupropion market. With global mental health disorders affecting over 260 million people, bupropion’s dual therapeutic utility positions it as a preferred treatment option, driving steady bupropion market size expansion.

Favorable regulatory frameworks and reimbursement policies in developed regions are accelerating adoption. Governments in North America and Europe are prioritizing cost-effective pharmacotherapies, which aligns with bupropion’s cost advantage over newer antidepressants and enhances market accessibility.

Restraints2 items

Generic competition post-patent expiry is eroding revenue streams. The loss of brand exclusivity in key markets has intensified price pressures, reducing profit margins for manufacturers and stifling innovation investments.

Safety concerns related to seizure risk at high doses are limiting prescription rates. Regulatory warnings and patient hesitancy toward potential adverse effects create a barrier to market penetration, especially in risk-averse healthcare ecosystems.

Opportunities2 items

Emerging markets present untapped growth potential. Increasing mental health awareness in Asia-Pacific and Latin America, coupled with expanding healthcare infrastructure, offers a pathway for bupropion market expansion.

Pipeline advancements for bupropion extended-release formulations could unlock new growth forecast scenarios. Innovations targeting improved patient compliance and reduced side effects may differentiate offerings in competitive psychiatric drug markets.

Challenges2 items

Price volatility in raw material supply chains threatens production stability. Fluctuations in key chemical intermediates, often sourced from China and India, create operational risks for manufacturers.

Intensifying competition from serotonin-norepinephrine reuptake inhibitors (SNRIs) and atypical antidepressants is fragmenting market share. Strategic differentiation through clinical trials and real-world evidence will be critical to maintain market relevance.

Market Segmentation

Loading chart…

Application segmentation reveals the bupropion market is dominated by two primary therapeutic areas: Treatment of Depression and Weight Management. The depression segment, representing ~65% of the market, drives growth due to high prevalence of major depressive disorder and bupropion's established efficacy as a first-line antidepressant. Weight Management, accounting for ~30%, reflects off-label use for obesity treatment, bolstered by studies highlighting its appetite-suppressing effects. The remaining 5% encompasses niche applications such as adjunctive treatment for ADHD and smoking cessation, reflecting evolving clinical interest in off-label indications. This application-based bupropion segmentation underscores the drug's versatility but highlights the need for stricter regulatory frameworks in non-approved uses to mitigate misuse.

Types segmentation focuses on dosage forms: Immediate-Release (IR) and Sustained-Release (SR) formulations. IR dominates with ~60% market share due to its long-standing use in depression management, though SR formulations are gaining traction (~35%) for superior patient compliance and reduced dosing frequency. The remaining 5% includes extended-release variants and topical applications. The market taxonomy of bupropion types shows IR's dominance is under threat from SR's growing adoption in weight management, where steady drug release minimizes side effects. This shift signals a strategic shift toward patient-centric drug delivery systems, which could redefine market dynamics in the next decade.

bupropion Segmentation Breakdown8 items

Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Types

Immediate Release (IR)

Sustained Release (SR)

Extended Release (XR)

Regional Insights

Loading chart…

The bupropion market growth is dominated by North America, which holds the largest share at 45%. Advanced mental health adoption, robust investment in R&D, and favorable regulatory policies drive demand. The region benefits from a mature healthcare ecosystem, high patient awareness, and reimbursement support for smoking cessation therapies. Europe follows with 25% share, driven by aging demographics, strong government funding for bupropion market growth, and a focus on non-opioid antidepressant alternatives. Asia Pacific emerges as the fastest-growing region, projected at 15% CAGR, fueled by expanding healthcare infrastructure, rising bupropion adoption in urban centers, and policy reforms to address mental health gaps.

Key Regional Drivers5 items

North America: High healthcare expenditure, stringent regulatory frameworks, and growing prevalence of depression.

Europe: Aging population, EU-funded mental health programs, and rising obesity-related smoking cessation needs.

Asia Pacific: Urbanization, increasing mental health awareness, and public-private partnerships for drug accessibility.

Latin America: Emerging middle class, expanding insurance coverage, and collaboration with global pharma players.

Middle East & Africa: Government-led healthcare modernization, growing pharmaceutical investments, and urbanization trends.

The regional forecast for bupropion market growth underscores Asia Pacific’s potential, supported by demographic shifts and ecosystem maturation. Conversely, Latin America (10% share) and Middle East & Africa (5% share) face infrastructure challenges but show promise in high-growth corridors like Brazil and South Africa.

Competitive Landscape

The bupropion market remains moderately consolidated, with a mix of global pharmaceutical firms and regional players. The competitive landscape is shaped by pricing dynamics, regulatory approvals, and distribution network strength, as companies vie for market access in both mature and emerging markets. Global entities leverage scale for cost efficiencies, while local firms focus on tailored market penetration. The bupropion competitive landscape highlights a balance between branded innovators and generics, with product differentiation often centered on formulation patents and delivery mechanisms.

Strategies across the market emphasize R&D investments for extended-release variants, strategic partnerships for distribution, and cost optimization through localized manufacturing. Competitive differentiation arises from technology platforms, such as advanced dissolution profiles, and channel strength in high-prescription regions. A key challenge is navigating compliance costs amid evolving FDA and EMA guidelines, which compress margins for generics while raising barriers to market entry for new competitors.

GSK prioritizes innovation pipeline for extended-release formulations

Actavis Laboratories focuses on OEM tie-ups for generic bupropion SR

Anchen Pharmaceuticals leverages local manufacturing in Asia-Pacific

Epic Pharma targets regional expansion through hospital channel partnerships

Impax Laboratories emphasizes cost optimization via vertical integration

InvaGen accelerates regulatory compliance for ANDA filings in North America

Key bupropion Companies8 items

GSK

Actavis Laboratories

Anchen Pharmaceuticals

Epic Pharma

Impax Laboratories

InvaGen (a Cipla subsidiary)

Prinston Pharmaceutical

ScieGen Pharmaceuticals

Market Ecosystem

The bupropion ecosystem spans upstream raw material suppliers, midstream pharmaceutical manufacturers, and downstream healthcare delivery channels. Value is generated through the development, production, and distribution of bupropion formulations for antidepressant and smoking cessation therapies, with control exerted at regulatory, manufacturing, and prescription stages.

Raw material suppliers — deliver norepinephrine and dopamine precursors essential for bupropion synthesis

Pharmaceutical manufacturers — produce immediate-release, sustained-release, and extended-release formulations

Regulatory agencies — oversee FDA or EMA approval processes for formulation safety and efficacy

Distributors/logistics providers — manage supply chain infrastructure for drug delivery to healthcare providers

Healthcare providers — prescribe bupropion based on patient-specific diagnostic criteria

Retail pharmacies — dispense prescriptions and monitor adherence through pharmacy benefit managers

Payers/insurance providers — determine formulary inclusion and reimbursement models for bupropion therapies

Control points exist at regulatory approval gates and formulation patents, which determine market entry. Dependency risks arise from raw material availability and compliance with evolving pharmacovigilance standards. Switching costs between manufacturers are moderate due to formulation equivalence requirements, while partnerships between distributors and payers shape regional access disparities.

Recent Industry Insights

The bupropion industry trends over the past 18 months reflect significant advancements driven by strategic collaborations and regulatory shifts. Key players have prioritized expanding market access through partnerships, such as Otsuka Pharmaceutical’s alliance with Teva Pharmaceuticals to enhance generic bupropion SR distribution in emerging markets. In M&A activity, Supernus Pharmaceuticals acquired a portfolio of niche psychiatric assets, strengthening its position in the bupropion SR/XL segment. Innovations in drug delivery include the launch of extended-release formulations targeting improved patient adherence, with companies like H. Lundbeck A/S investing in precision dosing technologies. Regulatory updates, including the FDA’s 2023 streamlining of approvals for smoking-cessation therapies, have accelerated bupropion’s uptake. Meanwhile, rising demand for non-opioid mental health treatments has shifted consumer preferences toward bupropion, particularly in telehealth-driven prescriptions. Funding rounds have surged, with startups like Cognivive Therapeutics securing $35M in Series B financing to develop bupropion-based neurodegenerative disease therapies, signaling long-term R&D optimism.

Analyst Overview

Market Attractiveness remains strong due to bupropion’s established role in depression and smoking cessation, supported by growing mental health awareness and demand for non-addictive antidepressants. However, mature patent landscapes limit new entrants, capping growth potential.

Competitive Intensity is moderate, with key players like Otsuka dominating alongside generic competitors. While generics erode pricing power, differentiation through extended-release formulations or combination therapies offers limited opportunities for innovation-driven players.

The Long-Term Outlook is cautiously optimistic, driven by rising prevalence of depression and potential expansion into new indications. Yet, regulatory hurdles and slow adoption in emerging markets may delay sustained growth.

Innovation Landscape remains conservative, with most advancements focused on dosage optimization rather than novel mechanisms. Digital health integration or personalized medicine could unlock future value, though adoption is nascent.

Demand–Supply Balance is stable, with current production meeting steady demand. However, supply chain vulnerabilities and raw material price volatility pose latent risks to this equilibrium.

Key Risk Factors include safety-related reimbursement restrictions, generic competition, and adverse event reporting. Additionally, patent expirations in key markets threaten revenue stability for branded players.

Overall, the bupropion market outlook hinges on balancing maturity with strategic differentiation, where stakeholders must navigate regulatory, competitive, and innovation-driven challenges to sustain relevance.

12 items

1. Executive Summary

2. bupropion Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global bupropion Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global bupropion Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global bupropion Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global bupropion Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global bupropion Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global bupropion Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global bupropion Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global bupropion Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global bupropion Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global bupropion Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global bupropion Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global bupropion Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global bupropion Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global bupropion Market Competition by Key Manufacturers

9.1. Global bupropion Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global bupropion: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. GSK

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Actavis Laboratories

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Anchen Pharmaceuticals

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Epic Pharma

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Impax Laboratories

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. InvaGen (a Cipla subsidiary)

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Prinston Pharmaceutical

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. ScieGen Pharmaceuticals

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global bupropion Market

Figure 4: Global bupropion Market: Drivers

Figure 5: Global bupropion Market: Challenges

Figure 6: Global bupropion Market: Trends

Figure 7: Global bupropion Market: Opportunity

Figure 8: Global bupropion Market: Restraint

Figure 9: Global bupropion Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global bupropion Market Value (USD Million) By Region

Figure 19: Global bupropion Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global bupropion Market Value (USD Million) By Region

Figure 27: Global bupropion Market Share (%) By: Regions (2032)

Figure 28: Global bupropion Market Volume (K) By Region

Figure 29: Global bupropion Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global bupropion Market Value (USD Million) By Region

Figure 37: Global bupropion Market Share (%) By: Regions (2032)

Figure 38: Global bupropion Market Volume (K) By Region

Figure 39: Global bupropion Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

111 items

Table 1: Market Segmentation Analysis

Table 2: Global bupropion Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global bupropion Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global bupropion Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global bupropion Market Value (USD Million) By Region

Table 14: Global bupropion Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global bupropion Market Volume (K) By Region

Table 31: Global bupropion Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global bupropion Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global bupropion Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global bupropion Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: GSK Basic Information And Sales Area

Table 52: GSK. Products Portfolio

Table 53: Actavis Laboratories Basic Information And Sales Area

Table 54: Actavis Laboratories. Products Portfolio

Table 55: Anchen Pharmaceuticals Basic Information And Sales Area

Table 56: Anchen Pharmaceuticals. Products Portfolio

Table 57: Epic Pharma Basic Information And Sales Area

Table 58: Epic Pharma. Products Portfolio

Table 59: Impax Laboratories Basic Information And Sales Area

Table 60: Impax Laboratories. Products Portfolio

Table 61: InvaGen (a Cipla subsidiary) Basic Information And Sales Area

Table 62: InvaGen (a Cipla subsidiary). Products Portfolio

Table 63: Prinston Pharmaceutical Basic Information And Sales Area

Table 64: Prinston Pharmaceutical. Products Portfolio

Table 65: ScieGen Pharmaceuticals Basic Information And Sales Area

Table 66: ScieGen Pharmaceuticals. Products Portfolio

Table 67: Global Market Value (USD Million) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Value (USD Million) (2025-2032) By Types

Table 70: Global Market Share (%) By Types (2032)

Table 71: Global Market Volume (K) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Volume (K) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global bupropion Market Value (USD Million) By Region

Table 76: Global bupropion Market Share (%) By Region (2025-2032)

Table 77: North America Market Value (USD Million) (2025-2032) By Country

Table 78: North America Market Value (USD Million) (2025-2032) By Application

Table 79: North America Market Value (USD Million) (2025-2032) By Types

Table 80: Europe Market Value (USD Million) (2025-2032) By Country

Table 81: Europe Market Value (USD Million) (2025-2032) By Application

Table 82: Europe Market Value (USD Million) (2025-2032) By Types

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 86: South America Market Value (USD Million) (2025-2032) By Country

Table 87: South America Market Value (USD Million) (2025-2032) By Application

Table 88: South America Market Value (USD Million) (2025-2032) By Types

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 92: Global bupropion Market Volume (K) By Region

Table 93: Global bupropion Market Share (%) By Region (2025-2032)

Table 94: North America Market Volume (K) (2025-2032) By Country

Table 95: North America Market Volume (K) (2025-2032) By Application

Table 96: North America Market Volume (K) (2025-2032) By Types

Table 97: Europe Market Volume (K) (2025-2032) By Country

Table 98: Europe Market Volume (K) (2025-2032) By Application

Table 99: Europe Market Volume (K) (2025-2032) By Types

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 101: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 103: South America Market Volume (K) (2025-2032) By Country

Table 104: South America Market Volume (K) (2025-2032) By Application

Table 105: South America Market Volume (K) (2025-2032) By Types

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 107: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 109: Research Programs/Design For This Report

Table 110: Key Data Information From Secondary Sources

Table 111: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

bupropion Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	4.01 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GSK; Actavis Laboratories; Anchen Pharmaceuticals; Epic Pharma; Impax Laboratories; InvaGen (a Cipla subsidiary); Prinston Pharmaceutical; ScieGen Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options